护城河对比

The FY2025 20-F positions Nebius as 'one of the few global, at scale, multi-tenant clouds purpose built for AI,' but the same filing names its central dependency plainly: 'We currently rely on Nvidia for the GPU chips we use' — a purpose-built neocloud renting a supply the hyperscalers it competes with also control, which is a real but narrow position.

来源：sec.gov

宽阔：CUDA 软件平台及其开发者既有用户基础在整个 AI 训练技术栈上形成高昂的转换成本，由累计 $76.7B 研发投入护持，并被 FY2026 约 71% 的毛利率以及同比增长 68% 的数据中心营收（约占总额 90%）所强化——按 FY2026 10-K，这些是持久且难以复制的优势。

来源：sec.gov

Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K.

来源：sec.gov

The moat the filing describes is engineering: designs that 'optimize power and cooling efficiency, lower latency' plus 'a consistent track record of being one of the first-to-deploy the latest generation of NVIDIA GPU chips' — density and time-to-deploy at scale, not a switching lock.

来源：sec.gov

持久优势建立在专有 IP 与软件之上：可在所有 NVIDIA GPU 上运行的全栈 CUDA 开发平台，加上数百个专有领域库/SDK/API，以及累计 $76.7B 研发投入所带来的 "inventions that are essential to modern computing"（NVIDIA 于 1999 年发明了 GPU）。按 FY2026 10-K 的业务章节，这一优势还被开发者生态系统的网络效应与 CUDA 转换成本进一步强化。

来源：sec.gov

Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly.

来源：sec.gov

The 20-F's own claim is 'one of the FEW global, at scale' AI clouds — a differentiated challenger to the hyperscalers it names as the competitive field, not a claimed leader of it; the first-to-deploy record is a follower's speed advantage, not category leadership.

来源：sec.gov

FY2026 Data Center revenue was $193.7B (~90% of the $215.9B total), up 68% YoY on the Blackwell ramp, and NVIDIA describes itself as "a data center scale AI infrastructure company reshaping all industries." The 10-K frames named rivals as parties who "provide or intend to provide" GPUs/accelerators — incumbent-leader positioning.

来源：sec.gov

Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K.

来源：sec.gov

The filing frames a 'highly competitive' market with 'frequent introduction of new or improved solutions' and a GPU cost base set by a single supplier (NVIDIA) — a renter of compute competing on efficiency has little list-price control.

来源：sec.gov

FY2026 gross margin was 71.1% (75.0% in FY2025); per the 10-K MD&A the ~3.9pt decline reflects the Hopper HGX→Blackwell full-system mix shift and a one-time $4.5B H20 excess-inventory/purchase-obligation charge, not competitive price erosion. A low-70s% hardware gross margin evidences strong pricing power.

来源：sec.gov

Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong.

来源：sec.gov

Layer-8 neocloud — a purpose-built AI compute provider reselling NVIDIA silicon at scale.

Upstream compute-platform supplier: NVIDIA sells full-stack data-center systems (GPU + Arm CPU + DPU + NVLink/InfiniBand networking + CUDA software) to cloud providers and enterprises, and relies on third-party foundry/assembly-test-packaging partners (e.g., SPIL, Amkor, Wistron, Fabrinet). Per the FY2026 10-K, several of its largest customers (hyperscalers such as Amazon, Alphabet, Microsoft) are simultaneously customers and emerging competitors developing internal accelerated-computing silicon.

Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect.

• Nebius AI cloud (GPU compute + managed AI/ML platform) 挑战者 · 中等 来源：sec.gov
• Toloka / Avride / TripleTen (non-cloud segments) 未知 · 低 来源：sec.gov

• CUDA accelerated-computing software platform (CUDA-X, NVIDIA AI Enterprise) 领先 · 深 来源：sec.gov
• Data Center AI accelerators (GPU — Blackwell/Hopper) 领先 · 深 来源：sec.gov
• Data-center networking / interconnect (NVLink, InfiniBand, Spectrum Ethernet, DPUs) 前三 · 中等 来源：sec.gov

• Mounjaro (tirzepatide) 前三 · 深 来源：sec.gov
• Verzenio (abemaciclib) 领先 · 中等 来源：living.tech
• Zepbound (tirzepatide) 领先 · 深 来源：sec.gov

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →